Diagnosis of Growth Hormone Deficiency in Adults: Provocative Testing with GHRP6 in Comparison to the Insulin Tolerance Test

Abstract

The aim of the study was to evaluate the clinical applicability of growth hormone releasing peptide 6 (GHRP6) for the diagnosis of GH deficiency in adults. Forty-nine patients with suspected hypothalamic or pituitary disease underwent both ITT and GHRP6 (1 μg/kg) testing. In addition, 20 healthy controls were tested by GHRP6 only. Blood samples were analyzed for GH levels. Thirty patients had a GH peak response of less than 3 μg/l during ITT and were considered growth hormone deficient (GHD). For the GHRP6 test, the GH mean peak was 3.0 μg/l (±0.8, 0.5–20.9) in the GHD group vs. 14.8 μg/l (±4.7, 1.8–95.3) in the growth hormone sufficient (GHS) group. Receiver operating characteristics (ROC) analysis suggested an optimal peak GH cut-point of 3.5 μg/l with 80% sensitivity and 95% specificity. Applying upper (11.3 μg/l) and lower (3.5 μg/l) cutoffs with high specificities established the diagnosis in nearly two third of the patients. During administration of GHRP6 no side effects were observed. GHRP6 alone as a provocative test is highly specific, but with limited sensitivity for the diagnosis of GH deficiency in adults. Using upper and lower cutoffs, further testing by ITT may be necessary in only one-third of patients.

Key words

growth hormone secretagogues - ghrelin - insulin tolerance test

References

• 1 Carroll PV, Christ ER, Bengtsson BA, Carlsson L, Christiansen JS, Clemmons D, Hintz R, Ho K, Laron Z, Sizonenko P, Sonksen PH, Tanaka T, Thorne M. Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. Growth Hormone Research Society Scientific Committee.  J Clin Endocrinol Metab. 1998;  83 382-395
• 2 Gomez JM, Gomez N, Fiter J, Soler J. Effects of long-term treatment with GH in the bone mineral density of adults with hypopituitarism and GH deficiency and after discontinuation of GH replacement.  Horm Metab Res. 2000;  32 66-70
• 3 Ho KK. Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: a statement of the GH Research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine Society, and Endocrine Society of Australia.  Eur J Endocrinol. 2007;  157 695-700
• 4 Aimaretti G, Corneli G, Razzore P, Bellone S, Baffoni C, Arvat E, Camanni F, Ghigo E. Comparison between insulin-induced hypoglycemia and growth hormone (GH)-releasing hormone+arginine as provocative tests for the diagnosis of GH deficiency in adults.  J Clin Endocrinol Metab. 1998;  83 1615-1618
• 5 Frieboes RM, Murck H, Maier P, Schier T, Holsboer F, Steiger A. Growth hormone-releasing peptide-6 stimulates sleep, growth hormone, ACTH and cortisol release in normal man.  Neuroendocrinology. 1995;  61 584-589
• 6 Ghigo E, Arvat E, Muccioli G, Camanni F. Growth hormone-releasing peptides.  Eur J Endocrinol. 1997;  136 445-460
• 7 Smith RG, Ploeg LH Van der, Howard AD, Feighner SD, Cheng K, Hickey GJ, Wyvratt  Jr  MJ, Fisher MH, Nargund RP, Patchett AA. Peptidomimetic regulation of growth hormone secretion.  Endocr Rev. 1997;  18 621-645
• 8 Fairhall KM, Mynett A, Robinson IC. Central effects of growth hormone-releasing hexapeptide (GHRP-6) on growth hormone release are inhibited by central somatostatin action.  J Endocrinol. 1995;  144 555-560
• 9 Akman MS, Girard M, O’Brien LF, Ho AK, Chik CL. Mechanisms of action of a second generation growth hormone-releasing peptide (Ala-His-D-beta Nal-Ala-Trp-D-Phe-Lys-NH₂) in rat anterior pituitary cells.  Endocrinology. 1993;  132 1286-1291
• 10 Korbonits M, Kaltsas G, Perry LA, Grossman AB, Monson JP, Besser GM, Trainer PJ. Hexarelin as a test of pituitary reserve in patients with pituitary disease.  Clin Endocrinol (Oxf). 1999;  51 369-375
• 11 Petersenn S, Jung R, Beil FU. Diagnosis of growth hormone deficiency in adults by testing with GHRP-6 alone or in combination with GHRH: comparison with the insulin tolerance test.  Eur J Endocrinol. 2002;  146 667-672
• 12 Nargund RP, Patchett AA, Bach MA, Murphy MG, Smith RG. Peptidomimetic growth hormone secretagogues. Design considerations and therapeutic potential.  J Med Chem. 1998;  41 3103-3127
• 13 Codd EE, Shu AY, Walker RF. Binding of a growth hormone releasing hexapeptide to specific hypothalamic and pituitary binding sites.  Neuropharmacology. 1989;  28 1139-1144
• 14 Arvat E, Ceda GP, Vito L Di, Ramunni J, Gianotti L, Broglio F, Deghenghi R, Ghigo E. Age-related variations in the neuroendocrine control, more than impaired receptor sensitivity, cause the reduction in the GH-releasing activity of GHRPs in human aging.  Pituitary. 1998;  1 51-58
• 15 Popovic V, Leal A, Micic D, Koppeschaar HP, Torres E, Paramo C, Obradovic S, Dieguez C, Casanueva FF. GH-releasing hormone and GH-releasing peptide-6 for diagnostic testing in GH-deficient adults.  Lancet. 2000;  356 1137-1142
• 16 Massoud AF, Hindmarsh PC, Brook CG. Hexarelin-induced growth hormone, cortisol, and prolactin release: a dose-response study.  J Clin Endocrinol Metab. 1996;  81 4338-4341
• 17 Rahim A, O’Neill PA, Shalet SM. The effect of chronic hexarelin administration on the pituitary-adrenal axis and prolactin.  Clin Endocrinol (Oxf). 1999;  50 77-84
• 18 Chihara K, Shimatsu A, Hizuka N, Tanaka T, Seino Y, Katofor Y. A simple diagnostic test using GH-releasing peptide-2 in adult GH deficiency.  Eur J Endocrinol. 2007;  157 19-27

Correspondence